[2022 National Audit] "Madecassol" Bought from Market Kurly Is Not a Medicine?
Data from the Office of Yoo Ui-dong, People Power Party
[Asia Economy Reporter Lee Ji-eun] There have been frequent cases where 'quasi-drugs,' which have weak effects on the human body, are labeled and advertised in a way that causes them to be mistaken for pharmaceuticals, highlighting the need for active government intervention.
On the 11th, Yoo Ui-dong, a member of the National Assembly's Political Affairs Committee from the People Power Party, pointed out that quasi-drugs currently sold on online shopping malls, such as 'Plant-based Madecassol' and 'Uru Shot,' are being labeled and advertised in a way that misleads consumers into thinking they are pharmaceuticals.
According to the Pharmaceutical Affairs Act, pharmaceuticals and quasi-drugs are clearly distinguished. Products classified as quasi-drugs refer to those that have weak or indirect effects on the human body.
However, Yoo pointed out that quasi-drugs are being sold as pharmaceuticals on popular internet shopping malls. For example, Market Kurly, famous for its dawn delivery service, sells 'Plant-based Madecassol' and 'Uru Shot,' and most consumers who leave reviews believe that Madecassol and Uru Shot are general pharmaceuticals or over-the-counter drugs.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
However, these products are quasi-drugs and differ from the general pharmaceuticals 'Compound Madecassol' and 'Urusa.' Yoo emphasized, "Active supervision is necessary to prevent unnecessary harm and disputes caused by consumers mistaking quasi-drugs for real medicines." The Ministry of Food and Drug Safety responded that it will "review whether there is a violation of the Pharmaceutical Affairs Act and take appropriate measures."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.